Diagnostic and mechanistic implications of serum free light chains, albumin and alpha-fetoprotein in hepatocellular carcinoma

British Journal of Cancer

Volumn 110, Issue 9, 2014, Pages 2277-2282

  Teng, M ^a   Pirrie, S ^a   Ward, D G ^a   Assi, L K ^b   Hughes, R G ^b   Stocken, D ^a   Johnson, P J ^a,c  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^b Binding Site Group Ltd   (United Kingdom)

^c CLATTERBRIDGE CENTRE FOR ONCOLOGY   (United Kingdom)

Author keywords

albumin; alpha fetoprotein; biomarker; free light chains; hepatocellular carcinoma; proteomic; serum

Indexed keywords

ALBUMIN; ALPHA FETOPROTEIN; CYSTATIN C; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; IMMUNOGLOBULIN KAPPA CHAIN; IMMUNOGLOBULIN LAMBDA CHAIN; IMMUNOGLOBULIN LIGHT CHAIN; IMMUNOGLOBULIN M;

ALBUMIN BLOOD LEVEL; ALPHA FETOPROTEIN BLOOD LEVEL; AREA UNDER THE CURVE; ARTICLE; CHRONIC LIVER DISEASE; CLINICAL OBSERVATION; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; DIAGNOSTIC VALUE; DISCRIMINANT ANALYSIS; HUMAN; IMMUNOGLOBULIN BLOOD LEVEL; INTERMETHOD COMPARISON; KIDNEY FUNCTION TEST; LIVER CELL CARCINOMA; LIVER FUNCTION TEST; MAJOR CLINICAL STUDY; MASS SPECTROMETRY; PRIORITY JOURNAL; RECEIVER OPERATING CHARACTERISTIC; SEROLOGY; STANDARD;

ALPHA-FETOPROTEINS; CARCINOMA, HEPATOCELLULAR; HUMANS; IMMUNOGLOBULIN LIGHT CHAINS; LIVER NEOPLASMS; MASS SPECTROMETRY; SERUM ALBUMIN; TUMOR MARKERS, BIOLOGICAL;

EID: 84899936171     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2014.121     Document Type: Article

References (34)

1. Aggarwal R, Sequeira W, Kokebie R, Mikolaitis RA, Fogg L, Finnegan A, Plaas A, Block JA, Jolly M (2011) Serum free light chains as biomarkers for systemic lupus erythematosus disease activity. Arthritis Care Res 63(6): 891-898.
2. Assi LK, Hughes RG, Gunson B, Webb GM, Drayson MT, Bradwell AR, Adams DH (2010) Abnormally elevated serum free light chains in patients with liver disease. J Hepatol 51(s1): S440-S441.
3. Belanger L, Roy S, Allard D (1994) New albumin gene 3' adjacent to the alpha 1-fetoprotein locus. J Biol Chem 269(8): 5481-5484.
4. Bonis PA, Tong MJ, Blatt LM, Conrad A, Griffith JL (1999) A predictive model for the development of hepatocellular carcinoma, liver failure, or liver transplantation for patients presenting to clinic with chronic hepatitis C. Am J Gastroenterol 94(6): 1605-1612.
5. Bradwell AR, Carr-Smith HD, Mead GP, Tang LX, Showell PJ, Drayson MT, Drew R (2001) Highly sensitive, automated immunoassay for immunoglobulin free light chains in serum and urine. Clin Chem 47(4): 673-680.
6. Bruix J, Sherman M (2005) Management of hepatocellular carcinoma. Hepatology 42(5): 1208-1236.
7. Bruix J, Sherman M (2011) Management of hepatocellular carcinoma: an update. Hepatology 53(3): 1020-1022.
8. Carr BI, Kanke F, Wise M, Satomura S (2007) Clinical evaluation of lens culinaris agglutinin-reactive alpha-fetoprotein and des-gamma-carboxy prothrombin in histologically proven hepatocellular carcinoma in the United States. Dig Dis Sci 52(3): 776-782.
9. Child CG, Turcotte JG (1964) Surgery and portal hypertension. In The liver and portal hypertension, Child CG (ed). pp 50-64.
10. Gottenberg JE, Aucouturier F, Goetz J, Sordet C, Jahn I, Busson M, Cayuela JM, Sibilia J, Mariette X (2007) Serum immunoglobulin free light chain assessment in rheumatoid arthritis and primary Sjogren's syndrome. Ann Rheum Dis 66(1): 23-27.
11. Hann HW, Lee J, Bussard A, Liu C, Jin YR, Guha K, Clayton MM, Ardlie K, Pellini MJ, Feitelson MA (2004) Preneoplastic markers of hepatitis B virus-associated hepatocellular carcinoma. Cancer Res 64(20): 7329-7335.
12. Johnson PJ (2001) The role of serum alpha-fetoprotein estimation in the diagnosis and management of hepatocellular carcinoma. Clin Liver Dis 5(1): 145-159.
13. Kamath PS, Kim WR (2007) The model for end-stage liver disease (MELD). Hepatology 45(3): 797-805.
14. Katzmann JA, Clark RJ, Abraham RS, Bryant S, Lymp JF, Bradwell AR, Kyle RA (2002) Serum reference intervals and diagnostic ranges for free kappa and free lambda immunoglobulin light chains: relative sensitivity for detection of monoclonal light chains. Clin Chem 48(9): 1437-1444.
15. Keshgegian AA (1984) Hypoalbuminemia associated with diffuse hypergammaglobulinemia in chronic diseases: lack of diagnostic specificity. Am J Clin Pathol 81(4): 477-481.
16. Landgren O, Goedert JJ, Rabkin CS, Wilson WH, Dunleavy K, Kyle RA, Katzmann JA, Rajkumar SV, Engels EA (2010) Circulating serum free light chains as predictive markers of AIDS-related lymphoma. J Clin Oncol 28(5): 773-779.
17. Law SW, Dugaiczyk A (1981) Homology between the primary structure of alpha-fetoprotein, deduced from a complete cDNA sequence, and serum albumin. Nature 291(5812): 201-205.
18. Leerapun A, Suravarapu SV, Bida JP, Clark RJ, Sanders EL, Mettler TA, Stadheim LM, Aderca I, Moser CD, Nagorney DM, LaRusso NF, de Groen PC, Menon KV, Lazaridis KN, Gores GJ, Charlton MR, Roberts RO, Therneau TM, Katzmann JA, Roberts LR (2007) The utility of Lens culinaris agglutinin-reactive alpha-fetoprotein in the diagnosis of hepatocellular carcinoma: evaluation in a United States referral population. Clin Gastroenterol Hepatol 5(3): 394-402.
19. Marrero JA, El-Serag HB (2011) Alpha-fetoprotein should be included in the hepatocellular carcinoma surveillance guidelines of the American Association for the Study of Liver Diseases. Hepatology 53(3): 1060-1061.
20. Maurer MJ, Cerhan JR, Katzmann JA, Link BK, Allmer C, Zent CS, Call TG, Rabe KG, Hanson CA, Kay NE, Slager SL, Witzig TE, Shanafelt TD (2011) Monoclonal and polyclonal serum free light chains and clinical outcome in chronic lymphocytic leukemia. Blood 118(10): 2821-2826.
21. Nagao Y, Sata M (2010) Serum albumin and mortality risk in a hyperendemic area of HCV infection in Japan. Virol J 7: 375.
22. Poon TC, Yip TT, Chan AT, Yip C, Yip V, Mok TS, Lee CC, Leung TW, Ho SK, Johnson PJ (2003) Comprehensive proteomic profiling identifies serum proteomic signatures for detection of hepatocellular carcinoma and its subtypes. Clin Chem 49(5): 752-760.
23. Pugh RN, Murray-Lyon IM, Dawson JL, Pietroni MC, Williams R (1973) Transection of the oesophagus for bleeding oesophageal varices. Br J Surg 60(8): 646-649.
24. Sangiovanni A, Manini MA, Iavarone M, Romeo R, Forzenigo LV, Fraquelli M, Massironi S, Della CC, Ronchi G, Rumi MG, Biondetti P, Colombo M (2010) The diagnostic and economic impact of contrast imaging techniques in the diagnosis of small hepatocellular carcinoma in cirrhosis. Gut 59(5): 638-644.
25. Schuppan D, Afdhal NH (2008) Liver cirrhosis. Lancet 371(9615): 838-851.
26. Schwegler EE, Cazares L, Steel LF, Adam BL, Johnson DA, Semmes OJ, Block TM, Marrero JA, Drake RR (2005) SELDI-TOF MS profiling of serum for detection of the progression of chronic hepatitis C to hepatocellular carcinoma. Hepatology 41(3): 634-642.
27. Sterling RK, Jeffers L, Gordon F, Sherman M, Venook AP, Reddy KR, Satomura S, Schwartz ME (2007) Clinical utility of AFP-L3% measurement in North American patients with HCV-related cirrhosis. Am J Gastroenterol 102(10): 2196-2205.
28. Terrier B, Sene D, Saadoun D, Ghillani-Dalbin P, Thibault V, Delluc A, Piette JC, Cacoub P (2009) Serum free light chain assessment in hepatitis C virus-related lymphoproliferative disorders. Ann Rheum Dis 68(1): 89-93.
29. Torzilli G, MinagawaM, Takayama T, Inoue K, Hui AM, Kubota K, Ohtomo K, Makuuchi M (1999) Accurate preoperative evaluation of liver mass lesions without fine-needle biopsy. Hepatology 30(4): 889-893.
30. van der Heijden M, Kraneveld A, Redegeld F (2006) Free immunoglobulin light chains as target in the treatment of chronic inflammatory diseases. Eur J Pharmacol 533(1-3): 319-326.
31. Ward AM, Sheldon J, Rowbottom A, Wild GD (2004) PRU Handbook of Clinical Immunochemistry. PRU Publications: Rotherham, UK.
32. Ward DG, Cheng Y, N'Kontchou G, Thar TT, Barget N, WeiW, Billingham LJ, Martin A, Beaugrand M, Johnson PJ (2006a) Changes in the serum proteome associated with the development of hepatocellular carcinoma in hepatitis C-related cirrhosis. Br J Cancer 94(2): 287-292.
33. Ward DG, Cheng Y, N'Kontchou G, Thar TT, Barget N, Wei W, Martin A, Beaugrand M, Johnson PJ (2006b) Preclinical and post-treatment changes in the HCC-associated serum proteome. Br J Cancer 95(10): 1379-1383.
34. Wong VW, Chan SL, Mo F, Chan TC, Loong HH, Wong GL, Lui YY, Chan AT, Sung JJ, Yeo W, Chan HL, Mok TS (2010) Clinical scoring system to predict hepatocellular carcinoma in chronic hepatitis B carriers. J Clin Oncol 28(10): 1660-1665.